BeiGene announces their settlement of litigation against Brukinsa
Posted on November 25, 2024
Beigene has announced that they are entering into a settlement agreement with MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd. resolving patent litigation related to MSN’s Abbreviated New Drug Application seeking approval to market a generic version of BRUKINSA in the U.S.
Note that, under the terms of the agreement, MSN will not be able to sell a generic version of BRUKINSA earlier than June 15, 2037, subject to potential acceleration or extension under certain customary circumstances. The composition of matter patent for BRUKINSA, expiring in April 2034, was not challenged by MSN in the litigation.
“Developed internally, BRUKINSA is a best-in-class BTK inhibitor with the broadest label of any medicine in its class globally. This settlement reaffirms our confidence in the intellectual property protecting this groundbreaking treatment and its exclusivity. Approved in over 70 markets for treating diverse B-cell malignancies, BRUKINSA exemplifies the strength of our R&D program and reinforces our commitment to delivering transformative medicines around the world,” said Chan Lee, General Counsel at BeiGene. “We continue to advance our innovative oncology treatments, relying on a robust patent system to safeguard our investment. Our focus remains on expanding access to this therapy and future innovations for cancer patients globally.”
The settlement resolves all patent litigation brought by BeiGene against companies that sought to market generic versions of BRUKINSA. BeiGene and Sandoz Inc. previously filed a joint stipulation to dismiss patent litigation brought by BeiGene in response to Sandoz’s ANDA seeking approval to market a generic version of BRUKINSA.
Related Topics and Keywords
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy